The iQ Group Global, a consortium of life science and financial services companies which span the biopharma value chain from asset discovery to commercialization, has introduced the Saliva Glucose Biosensor.

This groundbreaking technology is the world's first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood. The saliva-based glucose test is being developed to improve the quality of life for over 425 million people living with diabetes globally.

The Saliva Glucose Biosensor comprises the Glucose Biosensor Unit and a digital healthcare app.  The Glucose Biosensor Unit is a small, disposable strip, which when exposed to an individual's saliva instantly provides a glucose measurement. The glucose measurement will be presented in real-time, via a proprietary digital app on a patient's smart device.

The iQ Group Global is currently working on a pilot research and development programme with the University of Newcastle to expand beyond the saliva glucose diagnostic test and develop the platform of Point of Care Diagnostic Tests beginning with tumor markers, hormones, and communicable diseases.